Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

BACKGROUND: Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and rec...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Lugner, Moa, Sattar, Naveed, Miftaraj, Mervete, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983265/
https://ncbi.nlm.nih.gov/pubmed/33752680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01258-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky